Haleon (LSE:HLN) Stock May Be 43% Undervalued On Cash Flow

Haleon has delivered a 10.9% total return over the past three years, which naturally puts the spotlight on whether today's share price lines up with the cash the business is expected to generate. With a Discounted Cash Flow (DCF) view available, the question now is how that performance stacks up against the intrinsic value implied by its future cash flows.

• The 10.9% three year return gives investors a concrete track record to weigh against what Haleon's future cash generation may be worth today.
• Haleon's focus on consumer health products can shape expectations for relatively steady demand and may support more predictable cash flow patterns than more cyclical sectors.
• Prefer to judge Haleon on earnings? See what Haleon's 19.3x P/E says about the price.

The issue now is whether Haleon's recent share price leaves enough alignment with the intrinsic value suggested by its expected cash flows.

If you are weighing whether Haleon's current price fairly reflects its cash flows, it can help to compare that question across 8 high quality undervalued stocks.

Is Haleon a Bargain on Cash Flow?

The Discounted Cash Flow (DCF) model values Haleon by estimating the cash it can return to shareholders over time, then discounting those amounts back to today. On the cash side, the business has generated roughly £2.48b in free cash flow over the last twelve months, and analysts expect future free cash flows to stay in the multi billion pound range with a gently rising profile rather than sharp swings.

Those projections, when run through this two stage DCF, point to an estimated intrinsic value that sits substantially above the current £3.55 share price. For an investor, the key takeaway is that the market price implies more pressured cash generation or risk than the DCF inputs currently assume. Your view on Haleon's long term resilience in consumer health will drive whether that gap looks attractive or justified. Find out what Haleon could be worth using our Discounted Cash Flow (DCF) estimate.

The Haleon Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Haleon valuation puzzle leaves off by spelling out which paths for growth, profitability and earnings would need to play out for the share price to look materially higher or lower than it does today. Each one ties a fair value to a particular mix of catalysts and risks so you can track over time which version of Haleon's story is actually unfolding on the Community page.

Haleon pulls in two very different readings from the community, with one group flagging upside in execution and another stressing growth risks.

Bull case: 31% undervalued

"Extending the current productivity and AI programme, which has already delivered 140 basis points of gross margin improvement alongside SKU and formulation reduction, provides room for further structural cost savings..."

Discover why this Narrative puts Haleon at 31% undervalued.

Bear case: 15% overvalued

"Although Haleon continues to talk up premium, clinically supported oral health launches that have historically outgrown the wider category, the group is still only delivering 2.6% organic revenue growth in the first half of 2026 against a 4% to 6% ambition..."

Explore why this Narrative puts Haleon at 15% overvalued.

Haleon’s price is only one side of the story

Before treating Haleon’s valuation as the whole picture, it is worth knowing that Simply Wall St’s broader checks have flagged specific concerns that investors may want to weigh carefully next to the upside case. Take a closer look at 1 warning sign before settling on a valuation.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com